Track AbbVie Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AbbVie Inc. ABBV · Stock Open AbbVie Inc. in new tab

295.03 USD
P/E
50.61
EPS
5.83
Yield
2.39%
Safety Score
32
P/B
-113.78
ROE
6225.00
Beta
0.19
Target Price
311.81 USD
AbbVie Inc. logo

AbbVie Inc.

🧾 Earnings Recap – Q3 2026

AbbVie’s shares rose 1.3%, a roughly flat reaction, as third-quarter revenue and adjusted EPS came in above the company’s expectations and full-year revenue guidance increased. Skyrizi and Rinvoq drove immunology growth, while the call also highlighted continued Humira sales declines.

  • Third-quarter revenue was $17.4 billion, up more than 10%; adjusted EPS was $3.82, $0.07 above the company’s guidance midpoint.
  • AbbVie raised full-year revenue guidance by $200 million, bringing the total increase since the start of the year to $800 million.
  • Immunology revenue approached $9.2 billion, up 16.6% operationally. Skyrizi sales were nearly $5.8 billion, up 22.9%, and Rinvoq sales were $2.7 billion, up 24.3%.
  • Humira sales were $683 million, down 30%.
  • The company announced a 5.2% increase in its quarterly dividend, beginning with the payment in February 2027.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 3, 2027
P/E50.61
EPS5.83
Book Value-2.59
Price to Book-113.78
Debt/Equity4789.60
% Insiders0.319%
Growth
Revenue Growth0.10%
Earnings Growth22.82%
Estimates
Forward P/E18.22
Forward EPS16.20
Target Mean Price311.81
Dividend
Dividend Yield2.39%
Annual dividends6.92 USD
Ex-Div. DateJan. 15, 2027
Payout117.28%
5y avg Yield3.96%

DCF valuation

Model fair value for AbbVie Inc. (ABBV)
Result
Sign in to run the valuation for ABBV.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
26 analysts · consensus Buy · mean target 311.81 USD (low 237.00, high 350.00) · as of 15 Nov 2026
Low 237.00
Mean 311.81
High 350.00
Price 295.03
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

AbbVie Inc. Logo AbbVie Inc. Analysis (ABBV)

United States Health Care Official Website Stock

Is AbbVie Inc. a good investment? AbbVie Inc. (ABBV) is currently trading at 295.03 USD. Market analysts have a consensus price target of 311.81 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 50.61. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: AbbVie Inc. is expected to release its next earnings report on Feb. 3, 2027. The market consensus estimate for Forward EPS is 16.20.

For income investors, AbbVie Inc. pays a dividend yield of 2.39%. With a payout ratio of 117%, the dividend appears to be under pressure.

Investor FAQ

Does AbbVie Inc. pay a dividend?

Yes, it pays an annual dividend of 6.92 USD (2.39% yield).

What asset class is AbbVie Inc.?

AbbVie Inc. is classified as a Stock. You can compare it against 11 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 3, 2027. The company currently has a trailing EPS of 5.83.

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Exchange Ticker
BER (Germany) 4AB.BE
US00287Y1091
MEX (Mexico) ABBV.MX
VIE (Austria) ABBV.VI
SAO (Brazil) ABBV34.SA
DUS (Germany) 4AB.DU
FRA (Germany) 4AB.F
MUN (Germany) 4AB.MU
STU (Germany) 4AB.SG
NYQ (United States) ABBV
GER (Germany) 4AB.DE
Trades
Dividend Yield
2.39%
5y avg 3.96%
Annual Dividends
6.92USD
Next Ex. Div Date
Jan. 15, 2027
Payout Ratio
117.28%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
5.53 USD
Aug. 16, 2027 (estimated) 1.8525
May 17, 2027 (estimated) 1.8525
Feb. 16, 2027 1.8200
▸2026
6.92 USD
Nov. 16, 2026 1.7300
Aug. 14, 2026 1.7300
May 15, 2026 1.7300
Feb. 17, 2026 1.7300
▸2025
6.56 USD
Nov. 14, 2025 1.6400
Aug. 15, 2025 1.6400
May 15, 2025 1.6400
Feb. 14, 2025 1.6400
▸2024
6.20 USD
Nov. 15, 2024 1.5500
Aug. 15, 2024 1.5500
May 15, 2024 1.5500
Feb. 15, 2024 1.5500
▸2023
5.92 USD
Nov. 15, 2023 1.4800
Aug. 15, 2023 1.4800
May 15, 2023 1.4800
Feb. 15, 2023 1.4800
▸2022
5.64 USD
Nov. 15, 2022 1.4100
Aug. 15, 2022 1.4100
May 16, 2022 1.4100
Feb. 15, 2022 1.4100
▸2021
5.20 USD
Nov. 15, 2021 1.3000
Aug. 16, 2021 1.3000
May 14, 2021 1.3000
Feb. 16, 2021 1.3000
▸2020
4.72 USD
Nov. 16, 2020 1.1800
Aug. 14, 2020 1.1800
May 15, 2020 1.1800
Feb. 14, 2020 1.1800
▸2019
4.28 USD
Nov. 15, 2019 1.0700
Aug. 15, 2019 1.0700
May 15, 2019 1.0700
Feb. 15, 2019 1.0700
▸2018
3.59 USD
Nov. 15, 2018 0.9600
Aug. 15, 2018 0.9600
May 15, 2018 0.9600
Feb. 15, 2018 0.7100
▸2017
2.56 USD
Nov. 15, 2017 0.6400
Aug. 15, 2017 0.6400
May 15, 2017 0.6400
Feb. 15, 2017 0.6400
▸2016
2.28 USD
Nov. 15, 2016 0.5700
Aug. 15, 2016 0.5700
May 16, 2016 0.5700
Feb. 16, 2016 0.5700
▸2015
2.02 USD
Nov. 16, 2015 0.5100
Aug. 14, 2015 0.5100
May 15, 2015 0.5100
Feb. 13, 2015 0.4900
▸2014
1.66 USD
Nov. 17, 2014 0.4200
Aug. 15, 2014 0.4200
May 15, 2014 0.4200
Feb. 14, 2014 0.4000
▸2013
1.60 USD
Nov. 15, 2013 0.4000
Aug. 15, 2013 0.4000
May 15, 2013 0.4000
Feb. 15, 2013 0.4000
Upcoming Dividends
Name Payment Date Status Amount
AbbVie Inc. Feb 16, 2027 Upcoming 1.82 USD
AbbVie Inc. Nov 16, 2026 1.73 USD
AbbVie Inc. Aug 14, 2026 1.73 USD
AbbVie Inc. May 15, 2026 1.73 USD
AbbVie Inc. Feb 17, 2026 1.73 USD
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion